anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Resistant starch (RS) is a type of dietary fiber that provides fermentable carbohydrate (FC) in the lower bowel yielding positive effects on postprandial glycemia and weight management as well as digestive tract health. RS is defined as the portion of starch resistant to digestion by amylases, allowing it to reach the distal intestine where it can be fermented by the resident intestinal microbiota. A limited number of human studies using RS from high amylose corn have demonstrated that RS increases synthesis of gut peptides that improve glucose homeostasis and insulin secretion. Based on these studies, the FDA has recently approved the following health claims for resistant starch derived from corn (RS2): lowering of blood glucose, blood cholesterol, and blood pressure; increased mineral absorption; improved laxation; and reduced energy intake. The purpose in the proposed "proof of concept" study here is to show that RS provided in the form of wheat flour products has similar beneficial effects. The investigators aim to further explore the effect of RS on the gut microbiota. The intestinal microbiome is comprised of over one trillion bacterial cells comprised of approximately one thousand species that perform diverse functions ranging from energy harvest, angiogenesis, immunomodulation, and regulation of mood and behavior. Some of the major products of bacterial metabolism include acetate, propionate, and butyrate, the major short chain fatty acids (SCFA). These bioactive fermentation products have been associated with improved glucose homeostasis, attributed, in part, by their interactions with receptors on intestinal cells to augment secretion of glucagon-like peptide-1 (GLP-1), an incretin hormone known to stimulate insulin secretion.

This study is a randomized, cross-over design consisting of two 1-week dietary intervention periods as well as a 2-week washout period in between. Subjects will be randomly assigned to receive either RS wheat first or regular wheat first, then will be crossed over to the opposite treatment following a 2-week washout period. Wheat products made from RS wheat and regular wheat will be provided and the volunteers will be instructed to incorporate the products into their usual diet for 7 days. This study will probe the associations between the gut microbiota profiles, fermentation of RS wheat, microbial-mediated alterations in bile acids, and glycemia. The investigators will measure these effects in healthy, middle-aged humans using an interdisciplinary approach that integrates nutrition, microbiology, intestinal physiology, and analytical chemistry.
Typically people need separate prosthetic feet for running and walking. To bridge the gap, this study will test the Compliant Adaptive Energy Storage and Return (CAESAR) foot. This foot can change from a walk mode to a run mode with the push of a button. The investigators will test and improve this foot design mechanically, and then test this design on individuals with lower limb amputation in a lab setting. The goal of this project is to develop a passive prosthetic foot that can serve two purposes in someone's daily life: walking and running, to allow them to be more active. Here we will test this device to determine how it affects the user's mechanics during running and walking. Participants will come to a research laboratory for three test sessions where they will run and walk in their current foot, a commercial high-activity foot, and the prototype CAESAR foot.
PURPOSE:To prepare a standard serum which is stable for a long period of time without having turbidity by treating a serum for the standard serum with a prescribed water soluble high polymer compd. CONSTITUTION:A water soluble high polymer compd. expressed by the general formula ( I ) shown in the figure, for example, polyethylene glycol, PVA or the like, more preferably polyethylene glycol, more particularly, polyethylene glycol 6000 is first mixed with a serum, and thereafter the mixture is left to stand for about 10min at a room temp. and is then centrifugally separated for about 20min. The supernatant liquid is drawn by decantation after the centrifugal sepn. and is diluted to a prescribed standard serum value with a physiological salt soln. or the like. The turbidity in the standard serum can be eliminated by such simple operation and since the standard serum prepd. in such a way is stable for a long period of time, an exact calibration curve is formed by using the same and analysis of various components of the specimen with good accuracy is accomplished.
PURPOSE: A novel KIAA1764 for cell apoptosis or aging is provided to promote prevent and treat disease relating to cell apoptosis and/or aging. CONSTITUTION: A protein for controlling cell apoptosis or cell aging contains an amino acid sequence of sequence number 2 or 4. A gene for controlling cell apoptosis or aging encodes an amino acid sequence of sequence number 2 or 4. The gene has a nucleic acid of sequence number 1 or 3. A recombinant vector containing the gene contains the gene. A pharmaceutical composition contains a protein for controlling cell apoptosis or aging, the gene, or the recombinant vector. The pharmaceutical composition is used for preventing or treating diseases relating to cell apoptosis.
Participants were treated with JUVÉDERM® VOLUMA® with Lidocaine injectable gel during the 24-week Control Period. Participants were eligible for touch-up treatment 8 weeks after the initial treatment, if applicable. Follow-up continued in the 24-week Post-Control period.
Development of back pain is multifactorial, and it is not well understood which factors are the main drivers of the disease. We therefore applied a machine-learning approach to an existing large cohort study data set and sought to identify and rank the most important contributors to the presence of back pain amongst the documented parameters of the cohort. Data from 399 participants in the KORA-MRI (Cooperative health research in the region Augsburg-magnetic resonance imaging) (Cooperative Health Research in the Region Augsburg) study was analyzed. The data set included MRI images of the whole body, including the spine, metabolic, sociodemographic, anthropometric, and cardiovascular data. The presence of back pain was one of the documented items in this data set. Applying a machine-learning approach to this preexisting data set, we sought to identify the variables that were most strongly associated with back pain. Mediation analysis was performed to evaluate the underlying mechanisms of the identified associations. We found that depression and anxiety were the 2 most selected predictors for back pain in our model. Additionally, body mass index, spinal canal width and disc generation, medium and heavy physical work as well as cardiovascular factors were among the top 10 most selected predictors. Using mediation analysis, we found that the effects of anxiety and depression on the presence of back pain were mainly direct effects that were not mediated by spinal imaging. In summary, we found that psychological factors were the most important predictors of back pain in our cohort. This supports the notion that back pain should be treated in a personalized multidimensional framework. PERSPECTIVE: This article presents a wholistic approach to the problem of back pain. We found that depression and anxiety were the top predictors of back pain in our cohort. This strengthens the case for a multidimensional treatment approach to back pain, possibly with a special emphasis on psychological factors.
Moexipril hydrochloride tablets are indicated for treatment of patients with hypertension. They may be used alone or in combination with thiazide diuretics.

In using moexipril hydrochloride tablets, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride tablets do not have a similar risk (see WARNINGS).

In considering use of moexipril hydrochloride tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS, Angioedema).
<P>PROBLEM TO BE SOLVED: To provide soybean monascus ingestible in a single body as it is even in a bean-like or powdery state without influencing gustatory sensation in taste and flavor, and widely usable as health food because of containing a large amount of GABA (γ-aminobutyric acid) having antihypertensive action and also aglycone type isoflavones effective to osteoporosis.  <P>SOLUTION: A method for producing the soybean monascus containing 30-100 mg/100g of γ-aminobutyric acid comprises using as the raw material crushed soybeans, inoculating a filamentous fungus belonging to the genus Monascus and culturing the product in the conditions as follows: 1. The water ratio of a medium is 40-60%.2. The pH of the medium is 4.5-5.0 in the first and middle periods of culture. 3. A room temperature in environment in culture is 30-35°C.4. The number of days of culture is 10-20 days.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis. The MMi consists of 3-4 weekly sessions of 30-90 min each with an intervener (psychologist, social worker, or nurse) who provides the necessary ingredients to foster a good therapeutic alliance (i.e., trust, warmth, empathy, neutrality, and authenticity), encourages self-exploration and systematically addresses different levels of meaning (i.e., situational, global, existential, historical).
An aqueous solution of flavin-adenine dinucleotide (F.A.D.), e.g. from cell extracts or fermentation broths, is purified by adsorbing the F.A.D. on to a phenolic cation-exchange resin at a pH of about 1.0-3.0 and then eluting the F.A.D. with an aqueous eluant having a pH of about 3.0-10.0.  The adsorbed F.A.D. may be washed with an acidic aqueous solution of pH less than about 3.0 which may contain an inorganic salt such as NaCl or NH4Cl, e.g. a solution of HCl/NaCl. The eluant may comprise water or deionized water or alkaline or acid solutions such a HCl or CH3COOH or buffer solutions having a suitable pH.  An aqueous organic eluant containing a water-miscible solvent such as MeOH, EtOH, Me2CO or pyridine may also be used.  The cation exchange resins used include those having sulphonic acid and methyl sulphonic acid radicals and may be used in the free or salt form, preferably the sodium or ammonium salt form.  The crude F.A.D. solution preferably contins an inorganic salt such as NaCl or NH4Cl in a concentration of about 1 mol. per litre.  The cation exchange resin is preferably used in a column and F.A.D. may be recovered from the eluate by concentrating by evaporation and adding a suitable organic solvent such as ethanol.
NEW MATERIAL:A tetrakis-(3-aminopropyl)ammonium salt expressed by formula I. EXAMPLE:Hydrochloride of tetrakis-(3-aminopropyl)ammonium. USE:Use as an anticancer agent is expected, because of the stabilizing action of nucleic acid structure and adjusting action of cell growth displayed. Further also activation of cell-free protein synthesis, antimutagenic, antimicrobial property and antiinfectivity is expected and useful in broad fields such as biochemistry, medical science, pharmacy, etc., as a physiologically active substance. PREPARATION:A compound expressed by formula II is reacted with a compound expressed by formula III to afford a compound expressed by formula IV, which is reacted with a compound expressed by formula V to provide a compound expressed by formula VI, which is treated with a reducing agent to give the tetrakis-(3-aminopropyl)ammonium salt. The compound expressed by formula II is obtained by reacting NH3 with CH2CHCN and reducing the resultant product or reducing N(CH2CH2CONH2)3.
The invention provides a magnetic mattress with an anti-cancer medicine bag. The periphery of a magnetic mattress body is provided with coating layers, a medicine bag is arranged on the magnetic mattress body at the lower face of an upper coating layer, and slide fasteners are sewn on the edges of the upper coating layer with the part of the medicine bag and a side coating layer of the magnetic mattress body. A medicine arranged in the medicine bag is the mixture of Chinese yews, hickory barks, Chinese mugworts and borneol. Because the anti-cancer medicine bag is arranged on the mattress body at the lower side of the upper coating layer of the magnetic mattress according to the magnetic mattress with the anti-cancer medicine bag, the magnetic mattress with the anti-cancer medicine bag has an anti-cancer action. According to the mattress, the effect of a pharmacological function is generated by the sleep of a human body under the magnetic action of the mattress and the action of the volatile component of the medicine in the medicine bag, and the action of prevention is generated to the occurrence of cancers. The magnetic mattress with the anti-cancer medicine bag is suitable for serving as a sleeping bedding with the action of preventing the cancers for use.
A composition includes  Andrographis paniculata  extract at about 20% to about 30% by weight of the total composition;  Withania somnifera  extract at about 16% to about 24% by weight of the total composition;  Moringa oleifera  extract at about 24% to about 36% by weight of the total composition; and  Ocimum sanctum  extract at about 20% to about 30% by weight of the total composition. The composition may be in the form of a capsule, a pill, or a tablet. A method of supporting, maintaining, or improving immunity in a mammal includes administering the composition to a mammal, where upper respiratory tract infection symptoms are reduced, concentration of C-Reactive protein in the blood of the mammal is decreased, or the concentration of Immunoglobulin G in the blood of the mammal is increased. The mammal may be a human. The improved immunity may be to a virus. The improved immunity may be to an upper respiratory tract infection.
Oesophageal cancer (EC) is a malignancy which accounts for a substantial number of cancer-related deaths worldwide. The molecular mechanisms underlying the pathogenesis of EC have not been fully elucidated. GSE17351 and GSE20347 data sets from the Gene Expression Omnibus (GEO) database were employed to screen differentially expressed genes (DEGs). Reverse transcription quantitative PCR (RT-qPCR) was used to examine hub gene expression. ECA-109 and TE-12 cells were transfected using the pcDNA3.1 expression vector encoding GABRP. The cell counting kit-8 (CCK-8), cell scratch and Transwell assays were performed to assess the effect of GABRP on EC cell proliferation, migration and invasion. Epithelial-mesenchymal transition (EMT)-associated protein levels were measured by Western blotting. Subsequently, CFTR was knocked down to verify whether GABRP affected biological events in EC cells by targeting CFTR. Seven hub genes were identified, including GABRP, FLG, ENAH, KLF4, CD24, ABLIM3 and ABLIM1, which all could be used as diagnostic biomarkers for EC. The RT-qPCR results indicated that the expression levels of GABRP, FLG, KLF4, CD24, ABLIM3 and ABLIM1 were downregulated, whereas the expression level of ENAH was upregulated. In vitro functional assays demonstrated that GABRP overexpression suppressed the proliferation, migration, invasion and EMT of EC cells. Mechanistically, GABRP promoted the expression of CFTR, and CFTR knockdown significantly counteracted the influence of GABRP overexpression on biological events in EC cells. Overexpression of GABRP inhibited EC progression by increasing CFTR expression, which might be a new target for EC treatment.
After the assessment, all participants will receive a printed booklet containing a description and recommendations for carrying out the exercise program at home, which will be characterized by general exercises (i.e., strengthening, mobilization). The individuals will be instructed to perform the exercises twice a week for 8 weeks, following the same duration on the experimental group. Participants will be monitored and supervised by another physiotherapist via messaging app or telephone calls, following the same procedures reported in the experimental group. In the first week of the intervention there will be two face-to-face sessions supervised by a physiotherapist to familiarize the participants with the exercises and explain the booklet, and provide instructions on the intervention. A further face-to-face session will take place half-way the intervention, to monitor the participants.
Atomoxetine is a selective norepinephrine reuptake inhibitor. Atomoxetine hydrochloride is the R(-) isomer as determined by x-ray diffraction. The chemical designation is (-)- N-Methyl-3-phenyl-3-( o-tolyloxy)-propylamine hydrochloride. The molecular formula is C 17H 21NO•HCl, which corresponds to a molecular weight of 291.82. The chemical structure is: 

Atomoxetine hydrochloride USP is a white to practically white solid, which has a solubility of 27.8 mg/mL in water.

Atomoxetine capsules USP are intended for oral administration only.

Each capsule contains atomoxetine hydrochloride USP equivalent to 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, or 100 mg of atomoxetine. The capsules also contain the following inactive ingredients: pregelatinized starch and simethicone emulsion. The empty hard gelatin capsule shells contain gelatin, titanium dioxide, and sodium lauryl sulfate. In addition, the 18 mg contains iron oxide yellow, 25 mg and 40 mg contains FD&C Blue No 2, 60 mg contains FD&C Blue No 2 and iron oxide yellow, 80 mg and 100 mg contain iron oxide red and iron oxide yellow. The capsules are printed with edible ink containing black iron oxide and shellac.
A method for generating protocol data of a specific medical process is described. The specific medical process comprises at least one measurement process preferably a radiological imaging process. The method comprises generating a first structured medical data object based on user-generated electronic medical data. The user-generated electronic medical data are created by an expert documenting the specific medical process. Further, the method includes generating a second structured medical data object by applying an automatic processing algorithm to automatically created electronic medical data. The electronic medical data refer to the specific medical process. Furthermore, the method comprises generating the protocol data based on the first structured medical data object and on the second structured medical data object, wherein the first and second structured medical data objects are compared to determine deviations. Moreover, a protocol data generation device is described. Furthermore, a medical process system is described.
BACKGROUND: Posaconazole is used for the prophylaxis and treatment of invasive fungal infections in critically ill patients. Standard dosing was shown to result in adequate attainment of the prophylaxis Cmin target (0.7 mg/L) but not of the treatment Cmin target (1.0 mg/L).
OBJECTIVES: To provide an optimized posaconazole dosing regimen for IV treatment of patients with invasive pulmonary aspergillosis in the ICU.
METHODS: A population pharmacokinetics (popPK) model was developed using data from the POSA-FLU PK substudy (NCT03378479). Monte Carlo simulations were performed to assess treatment Cmin and AUC0-24 PTA. PTA ≥90% was deemed clinically acceptable. PopPK modelling and simulation were performed using NONMEM 7.5.
RESULTS: Thirty-one patients with intensive PK sampling were included in the PK substudy, contributing 532 posaconazole plasma concentrations. The popPK of IV posaconazole was best described by a two-compartment model with linear elimination. Interindividual variability was estimated on clearance and volume of distribution in central and peripheral compartments. Posaconazole peripheral volume of distribution increased with bodyweight. An optimized loading regimen of 300 mg q12h and 300 mg q8h in the first two treatment days achieved acceptable PTA by Day 3 in patients <100 kg and ≥100 kg, respectively. A maintenance regimen of 400 mg q24h ensured ≥90% Cmin PTA, whereas the standard 300 mg q24h was sufficient to achieve the AUC0-24 target throughout 14 days, irrespective of bodyweight.
CONCLUSIONS: We have defined a convenient, optimized IV posaconazole dosing regimen that was predicted to attain the treatment target in critically ill patients with invasive aspergillosis.
PURPOSE: A cosmetic composition for hair containing Paeonia lactiflora-brewed water having resveratrol is provided to prevent scalp aging and cell damage. CONSTITUTION: A cosmetic composition for scalp or hair contains 0.01-10.0 weight% of Paeonia lactiflora-brewed water. The Paeonia lactiflora-brewed water is extracted by adding Paeonia lactiflora to soluble composition containing water and infusing active ingredients of Paeonia lactiflora at low temperature. The composition additionally contains extracts of Opunitia ficus-indica var. saboten, Glycyrrhiza uralensis, or cacao seed. The composition is used in the form of hair tonic, hair essence, hair serum, scalp treatment, hair treatment, hair conditioner, hair shampoo or hair lotion.
COVID-19 pandemic was accompanied by many healthcare-related issues. Concrete national data regarding the care performance of critical ill cases of COVID-19 does not exist in Korea. The current study aimed to describe the treatment outcome and healthcare resource utilization of critically ill COVID-19 patients. Our multicenter retrospective cohort study enrolled critically ill COVID-19 patients from 22 tertiary care hospitals in Korea. Inclusion criteria: (1) patients aged 19 years or older, (2) patients with laboratory-confirmed SARS-CoV-2 infection who received at least one of following initial treatments such as high-flow oxygen therapy (HFOT) or noninvasive ventilation (NIV) or invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation. During the study wave, a total of 1358 eligible participants were enrolled, with 21 institutions participating in the study. Among them, data from 1113 patients were available and analyzed. Of 921 (82.7%), 621 (55.8%) were supported by IMV. Of the 921 patients supported by HFOT or NIV, 438 (47.6%) recovered without IMV, 429 (46.6%) required IMV, and 54 died who DNR after NIV was applied. Prone position ventilation was administered to 163 (33.1%) patients with IMV and 25 (6.2%) patients with HFOT. Extracorporeal membrane oxygenation was administered to 128 (20.6%) patients treated with IMV. The overall mortality rate was 26.4%. In South Korea, mortality rates for patients with severe COVID-19 pneumonia have been shown substantial fatality, with the highest mortality rates observed in wave 3. The increased mortality rate in wave 3 could be associated with the rapid escalation of critically ill COVID-19 patients and the consequent saturation of intensive care unit capacities. Patients received NIV therapy and prone position ventilation more frequently in wave 3 as the number of cases increased.